Vitality Watch

Dossier pubmed observational 26-may-2026
Human cohort, case-control, or epidemiological association

GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated Lp(a) levels: A Multicenter retrospective study.

Key claim: In a propensity-matched retrospective cohort of adults with Lp(a) >50 mg/dL and obesity or type 2 diabetes, GLP-1 receptor agonist use was associated with substantially lower all-cause mortality and major adverse cardiovascular events.

Abstract

BACKGROUND: Elevated lipoprotein(a) [Lp(a)] is a well-established, genetically mediated risk factor for atherosclerotic cardiovascular disease (ASCVD), yet effective therapies targeting Lp(a) remain limited. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide cardiometabolic benefits in high-risk populations, but their impact among patients with elevated Lp(a) levels is not well defined. METHODS: We conducted a retrospective cohort study to evaluate cardiovascular outcomes associated with GLP-1RA therapy in adults with Lp(a) >50 mg/dL and comorbid obesity or type 2 diabetes. Patients were categorized into GLP-1RA users versus non-users and matched 1:1 using propensity scores based on demographics, cardiovascular risk factors, and baseline comorbidities. The primary outcome was all-cause mortality; secondary outcomes included major adverse cardiovascular events (MACE: myocardial infarction, ischemic stroke, and coronary revascularization). Hazard ratios (HR) with 95% confidence intervals (CI) were estimated using Cox proportional hazards models. RESULTS: Among 24,185 eligible patients, 3791 received a GLP-1RA. After matching, 3310 patients remained in each cohort with balanced baseline characteristics. Over a median follow-up of approximately two years, GLP-1RA use was associated with significantly lower all-cause mortality (HR 0.66, 95% CI 0.48-0.90) and reduced MACE (HR 0.68, 95% CI 0.60-0.76). Individual components, including myocardial infarction, ischemic stroke, and cardiovascular death, were also significantly decreased among GLP-1RA users. CONCLUSION: In patients with elevated Lp(a), GLP-1RA therapy was associated with substantial reductions in mortality and cardiovascular events. These findings suggest potential cardioprotective effects of GLP-1RAs in a high-risk population with limited therapeutic options and support further prospective evaluation.

Why this matters

Elevated Lp(a) is a genetically driven cardiovascular risk factor with no approved lowering therapy yet, so any signal that an already-widely-used class shifts hard outcomes in this subgroup is clinically salient. This is observational and propensity-matched rather than randomized, so it extends but does not confirm the SELECT-era cardioprotection story into the Lp(a)-high population — the causal question awaits a trial with prespecified Lp(a) stratification.

Source

Link

Briefing card

GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated Lp(a) levels: A Multicenter retrospective study.
Stage: observational · pubmed · 26-may-2026

If you have elevated Lp(a) with obesity or type 2 diabetes, this retrospective analysis links GLP-1 receptor agonist use to lower mortality and cardiovascular events in your subgroup, though it is observational, not a trial.

In a propensity-matched retrospective cohort of adults with Lp(a) >50 mg/dL and obesity or type 2 diabetes, GLP-1 receptor agonist use was associated with substantially lower all-cause mortality and major adverse cardiovascular events.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.ijcard.2026.134588

build build 880 · 2bcef25 · 2026-11-18